摘要
目的 :研究胃肠胰神经内分泌肿瘤(gastroenteropancreatic neuroendocrine neoplasms,GEP-NENs)北京医保患者的直接医疗费用,为评估该病对医保基金的影响提供数据信息。方法:收集某医院医保类型为北京医保的胃肠胰神经内分泌肿瘤患者的全部相关直接医疗费用,同时对患者住院期间所用药品费用做以分析。结果:GEP-NENs患者每人每年直接医疗费用为23 502.13元,北京医保支付比例约为66.27%。患者住院期间,药品总费用占总费用比例约为56.22%,针对GEP-NENs的药物和抗癌辅助药物费用所占比例较高。结论:GEP-NENs患者直接医疗费用花费较大,医保可以缓解其部分负担。但由于该病发病率低,因此对于整个医保基金影响相对较小。GEP-NENs患者在住院期间的药费占比相对较大,主要和疾病本身的治疗方式以及药物的不良反应相关。
Objective：The direct medical expenditure of treatment for gastroenteropancreatic neuroendocrine neoplasms patients with Beijing medical insurance was analyzed to evaluate if the expenditure of disease treatment affects the medical healthcare insurance fund.Methods：The data of gastroenteropancreatic neuroendocrine neoplasms patients from some hospital who have Beijing medical insurance was collected.All the direct medical expenditures and the hospitalization expenditures was analyzed.Results：The annual direct medical expenditure of gastroenteropancreatic neuroendocrine neoplasms patients with Beijing medical insurance was 23 502.13 Yuan for each person,taking 66.27% of Beijing healthcare payment.The total drug cost accounted for about 56.22% of total cost during hospitalization.The cost of drugs for GEP-NENs and anti-tumor adjuvant drugs were in a high proportion.Conclusion：The direct medical expenditure of treatment for gastroenteropancreatic neuroendocrine neoplasms patient is a little high,while the healthcare insurance can lessen patient＇s financial burden.And the incidence of GEP-NENs is low,so it will not influence the whole medical insurance too much.The drug cost during hospitalization usually has a high percentage in the whole expenditure,which is relation to the treatment ways and the side effects of drugs.
出处
《临床药物治疗杂志》
2017年第8期25-28,共4页
Clinical Medication Journal
关键词
胃肠胰神经内分泌肿瘤
北京医保
医疗费用
gastroenteropancreatic neuroendocrine neoplasms
Beijing medical insurance
medical expenditures
